Structural GenomiX (SGX) will provide its technology to help generate new lead compounds that will function as correctors of the delta F508 mutation in sufferers of cystic fibrosis.
They also appealed to the international community to come forward with funds to make it work and help stave off the risk of an influenza pandemic. The new
The license covers all areas of the world except Japan, China, Korea and Taiwan. Lurasidone, codenamed SM13496, is an atypical antipsychotic compound currently in phase II development for
According to the company, the new Megace ES is an advanced formulation of megestrol acetate oral suspension, an appetite stimulant most commonly prescribed by physicians. “Unintended weight loss
One of the trials is evaluating the triplet combination of Telcyta, a tumor-activated drug candidate, with standard doses of carboplatin and paclitaxel in 35 patients with advanced stages
Under the Merck-funded study, California-based ParAllele will utilize its proprietary single nucleotide polymorphism (SNP) genotyping technology to characterize the genetic changes in tumor samples identified by Merck. Further
Overactive bladder (OAB) is a condition marked by the strong, immediate need to go to the bathroom (urgency), desire to go to the bathroom quite often (frequency), and
Health problems in prisons are abundant. Not only do many prisoners already suffer from health problems on entering prison, but the experience of being incarcerated can easily exacerbate
The company has secured the rights to develop and market the oral DPP-IV inhibitor, known as TS-021, which is currently in phase I clinical development for the treatment
The program, known as Shared Health Community Connection (SHCC), will create a patient-centered health record that will allow healthcare staff to view a patient’s personal medical information via
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.